MedTrace Logo

Linperlisib Combined With Immunochemotherapy in Relapsed/Refractory LBCL

NCT06489808 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 89

Last updated 2024-07-08

No results posted yet for this study

Summary

To evaluate the efficacy and safety of Linperlisib combined with standard immunochemotherapy in patients with R/R LBCL.

Conditions

  • Relapsed/Refractory Large B-Cell Lymphoma

Interventions

DRUG

Linperlisib

Linperlisib RP2D D1-14

DRUG

Rituximab

rituximab 375 mg/m2 D0

DRUG

Gemcitabine

gemcitabine per regimen dosage

DRUG

Oxaliplatin

Oxaliplatin 130 mg/m2 D1

DRUG

Ifosfamide

Ifosfamide 5g/m2 D2

DRUG

Carboplatin

Carboplatin AUC=5mg/mL · min (maximum absolute dose/cycle = 800 mg)

DRUG

Etoposide

Etoposide 100mg/m2 D1-3

DRUG

Dexamethasone

Dexamethasone 40mg D1-4

DRUG

Cisplatin

Cisplatin 100mg/m2 D1, continuous intravenous infusion

DRUG

Ara-C

Ara-C 2g/m2 q12h D2

DRUG

Vinorelbine

Vinorelbine 20mg/m2 D1

DRUG

Mitoxantrone hydrochloride liposome

Mitoxantrone hydrochloride liposome 18mg/m2 D1

Sponsors & Collaborators

  • Institute of Hematology & Blood Diseases Hospital, China

    lead OTHER

Principal Investigators

  • Lugui Qiu · Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-28
Primary Completion
2026-12-31
Completion
2027-05-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06489808 on ClinicalTrials.gov